Novel EGFR Truncations as Biomarker and Target

Background

Three new truncation mutants have been discovered in primary human tumors and cell lines. These mutants may possess oncogenic activities and render some tumors resistant to certain inhibitors. These newly discovered mutants may be used as biomarkers for predicting patients? response to specific targeting agents.

Technology

Researchers at Stony Brook University discovered three new truncation mutants of EGFR in primary human tumors and cell lines. These mutations may be used as biomarkers for predicting a patients? response to anti-EGFR drugs, molecular diagnostic for micrometastasis/minimal residual disease monitoring or become new therapeutic targets for drug and antibody development.

Advantages

New EGFR truncation mutants may be used for predicting patients? response to EGFR targeting agents. - Could become new therapeutic targets for drug and antibody development.

Application

Biomarker for predicting patients? response to anti-EGFR drugs. - Therapeutic target for drug and antibody development.

Patent Status

Patented

Stage Of Development

Antibody developed; need clinical validation. PCT Publication No. WO 2011-140391

Licensing Potential

Development partner - Commercial partner - Licensing

Licensing Status

Available for license. The team seeks to develop and commercialize, by an exclusive or non-exclusive license agreement and/or sponsored research, with a company active in the area.

Additional Info

Additional Information:

https://stonybrook.technologypublisher.com/files/sites/8218---novel-egfr-truncations-as-biomarker-and-target.jpg Source: National Cancer Institute, unsplash.com/photos/fd0b-Bl4cFc, Unsplash Licence